Noxopharm Ltd. (AU:NOX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Noxopharm Limited is set to commence the HERACLES clinical trial, having secured a specialist supplier for the production of SOF-SKN, a novel drug aimed at treating cutaneous lupus erythematosus, an autoimmune disease. The company is on track with preparations, ensuring the drug meets high quality standards and regulatory requirements for the early 2025 first-in-human trials. This development is a part of Noxopharm’s broader efforts in the growing immunology market, targeting conditions that affect millions globally.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.